Evidence map›Paper›PMID 34906155›Full record

ArticleJournal of nanobiotechnology2021

Irinotecan/scFv co-loaded liposomes coaction on tumor cells and CAFs for enhanced colorectal cancer therapy.

Zhaohuan Li, Chunxi Liu, Chenglei Li, Fangqing Wang, Jianhao Liu, Zengjuan Zheng, Jingliang Wu, Bo Zhang

Open access · goldAbstract read
In one paragraph

Article in Journal of nanobiotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Zhaohuan Li *School of Pharmacy, Weifang Medical University Weifang, Shandong, 261053, People's Republic of China.
Chunxi Liu *Department of Pharmacy, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Ji'nan, 250012, Shandong, People's Republic of China.
Chenglei LiSchool of Pharmacy, Weifang Medical University Weifang, Shandong, 261053, People's Republic of China.
Fangqing WangSchool of Bioscience and Technology, Weifang Medical University, Weifang, 261053, Shandong, People's Republic of China.
Jianhao LiuSchool of Pharmacy, Weifang Medical University Weifang, Shandong, 261053, People's Republic of China.
Zengjuan ZhengSchool of Pharmacy, Weifang Medical University Weifang, Shandong, 261053, People's Republic of China.
Jingliang WuSchool of Bioscience and Technology, Weifang Medical University, Weifang, 261053, Shandong, People's Republic of China. jlwu2008@163.com.
Bo ZhangSchool of Pharmacy, Weifang Medical University Weifang, Shandong, 261053, People's Republic of China. zhangbo@wfmc.edu.cn.ORCID http://orcid.org/0000-0001-6070-8316
Weifang Medical University · CNQilu Hospital of Shandong University · CN

Funding

National Science Foundation of China 81803464Natural Science Foundations of Shandong Province ZR2018BH041Natural Science Foundations of Shandong Province ZR2020MC078
6 · The paper itself

Abstract

backgroundCancer-associated fibroblasts (CAFs), as an important component of stroma, not only supply the "soils" to promote tumor invasion and metastasis, but also form a physical barrier to hinder the penetration of therapeutic agents. Based on this, the combinational strategy that action on both tumor cells and CAFs simultaneously would be a promising approach for improving the antitumor effect.

resultsIn this study, the novel multifunctional liposomes (IRI-RGD/R9-sLip) were designed, which integrated the advantages including IRI and scFv co-loading, different targets, RGD mediated active targeting, R9 promoting cell efficient permeation and lysosomal escape. As expected, IRI-RGD/R9-sLip showed enhanced cytotoxicity in different cell models, effectively increased the accumulation in tumor sites, as well as exhibited deep permeation ability both in vitro and in vivo. Notably, IRI-RGD/R9-sLip not only exhibited superior in vivo anti-tumor effect in both CAFs-free and CAFs-abundant bearing mice models, but also presented excellent anti-metastasis efficiency in lung metastasis model.

conclusionIn a word, the novel combinational strategy by coaction on both "seeds" and "soils" of the tumor provides a new approach for cancer therapy, and the prepared liposomes could efficiently improve the antitumor effect with promising clinical application prospects.

Indexed as

IrinotecanLiposomesAnimalsAntineoplastic AgentsApoptosisCancer-Associated FibroblastsCell Line, TumorCoculture TechniquesColorectal NeoplasmsDrug Delivery SystemsFemaleMiceMice, Inbred BALB CNIH 3T3 CellsSingle-Chain AntibodiesAntineoplastic AgentsIrinotecanLiposomesSingle-Chain AntibodiesCancer-associated fibroblastsCo-cultured cellsColorectal cancerLiposomesSingle chain fragment variable

Identifiers

PMID34906155
PMCPMC8670172
OpenAlexW4200411806

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.